patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_166441 | REC_0009801 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 13.9 | 55 | female | 1 | 16 | 5.5 | 5 | osimertinib 80 mg daily | 6.6 | true | MSI-H | 2026-03-15T05:35:59.280535+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_940332 | REC_0009802 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 5.6 | 67 | female | 0 | 21 | 5 | 4 | pembrolizumab 200 mg q3w | 9.7 | false | MSS | 2026-03-15T05:35:59.280821+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_402610 | REC_0009803 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 11.4 | 65 | male | 0 | 16 | 5.3 | 6 | osimertinib 80 mg daily | 13.5 | true | MSI-H | 2026-03-15T05:35:59.281237+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_139782 | REC_0009804 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 18 | 4.6 | 66 | female | 1 | 55 | 5.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 25.5 | true | MSS | 2026-03-15T05:35:59.281500+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_931171 | REC_0009805 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 13.9 | 58 | male | 1 | 0 | 4.5 | 3 | alectinib 600 mg BID | 15 | true | MSS | 2026-03-15T05:35:59.281760+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_102474 | REC_0009806 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 10.6 | 73 | female | 2 | 8 | 6.8 | 1 | alectinib 600 mg BID | 13.3 | false | MSI-H | 2026-03-15T05:35:59.282022+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_371722 | REC_0009807 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 35 | 9.1 | 75 | female | 2 | 17 | 8 | 8 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:35:59.282273+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_943704 | REC_0009808 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 7.8 | 54 | male | 0 | 17 | 5.5 | 4 | sotorasib 960 mg daily | 11.1 | true | MSS | 2026-03-15T05:35:59.282525+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_542681 | REC_0009809 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 12.4 | 61 | male | 1 | 14 | 5.6 | 5 | osimertinib 80 mg daily | 14.5 | true | MSI-H | 2026-03-15T05:35:59.282780+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_990350 | REC_0009810 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 30 | 5.1 | 75 | female | 3 | 26 | 7.9 | 1 | pembrolizumab 200 mg q3w | 18.4 | true | MSS | 2026-03-15T05:35:59.283029+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_415609 | REC_0009811 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 30 | 7.1 | 59 | male | 1 | 51 | 5.5 | 0 | carboplatin + paclitaxel + pembrolizumab | 38.8 | false | MSS | 2026-03-15T05:35:59.283285+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_319044 | REC_0009812 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 31 | 4.6 | 62 | female | 0 | 13 | 4.1 | 5 | pembrolizumab 200 mg q3w | 8.1 | true | MSS | 2026-03-15T05:35:59.283539+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988197 | REC_0009813 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 2.7 | 71 | female | 2 | 42 | 3 | 5 | pembrolizumab 200 mg q3w | 8.3 | false | MSS | 2026-03-15T05:35:59.283795+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_566323 | REC_0009814 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 9.8 | 57 | male | 1 | 10 | 4.7 | 4 | entrectinib 600 mg daily | 17.8 | false | MSS | 2026-03-15T05:35:59.284048+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_491559 | REC_0009815 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 7 | 60 | male | 0 | 28 | 5 | 7 | carboplatin + paclitaxel + pembrolizumab | 8.3 | true | MSS | 2026-03-15T05:35:59.284397+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173636 | REC_0009816 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 12.7 | 77 | female | 1 | 19 | 4.5 | 5 | alectinib 600 mg BID | 18.9 | false | MSS | 2026-03-15T05:35:59.284775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_129104 | REC_0009817 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 5.7 | 61 | female | 1 | 7 | 5.3 | 2 | entrectinib 600 mg daily | 16.5 | true | MSS | 2026-03-15T05:35:59.285039+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262339 | REC_0009818 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 5 | 69 | female | 1 | 63 | 5.7 | 4 | carboplatin + paclitaxel + pembrolizumab | 4.6 | false | MSS | 2026-03-15T05:35:59.285278+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_808781 | REC_0009819 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 4.3 | 53 | male | 0 | 59 | 5.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 6.4 | false | MSS | 2026-03-15T05:35:59.285528+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_729211 | REC_0009820 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 31 | 13.9 | 59 | female | 0 | 20 | 3.1 | 1 | sotorasib 960 mg daily | 29.6 | false | MSI-H | 2026-03-15T05:35:59.285776+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_968521 | REC_0009821 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 7 | 62 | female | 1 | 55 | 4.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.1 | false | MSS | 2026-03-15T05:35:59.286019+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_727098 | REC_0009822 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 8.1 | 72 | female | 1 | 0 | 6.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 7.2 | false | MSS | 2026-03-15T05:35:59.286254+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_638068 | REC_0009823 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 13.3 | 53 | female | 0 | 10 | 6.8 | 6 | entrectinib 600 mg daily | 14.9 | true | MSI-H | 2026-03-15T05:35:59.286491+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_998223 | REC_0009824 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 7.4 | 60 | male | 1 | 39 | 5.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.6 | false | MSS | 2026-03-15T05:35:59.286728+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_194848 | REC_0009825 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 10.8 | 83 | female | 2 | 7 | 7.1 | 5 | sotorasib 960 mg daily | 5.6 | true | MSI-H | 2026-03-15T05:35:59.286963+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_521648 | REC_0009826 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 15.8 | 72 | female | 2 | 13 | 6.5 | 0 | osimertinib 80 mg daily | 18.6 | false | MSS | 2026-03-15T05:35:59.287202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_814923 | REC_0009827 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 7.6 | 75 | male | 1 | 20 | 5.4 | 1 | pembrolizumab 200 mg q3w | 20.5 | true | MSS | 2026-03-15T05:35:59.287452+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_904043 | REC_0009828 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 10.7 | 65 | female | 0 | 19 | 4.8 | 2 | entrectinib 600 mg daily | 12.1 | true | MSI-H | 2026-03-15T05:35:59.287702+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_731933 | REC_0009829 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 10.4 | 67 | female | 0 | 4 | 6.3 | 1 | sotorasib 960 mg daily | 21.2 | false | MSI-H | 2026-03-15T05:35:59.288064+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_830959 | REC_0009830 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 13.3 | 52 | female | 0 | 26 | 4.7 | 1 | alectinib 600 mg BID | 21.2 | true | MSS | 2026-03-15T05:35:59.288421+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_794316 | REC_0009831 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 8.1 | 64 | male | 0 | 20 | 5.5 | 1 | osimertinib 80 mg daily | 11 | true | MSS | 2026-03-15T05:35:59.288683+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_278174 | REC_0009832 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 12.4 | 67 | female | 0 | 10 | 5.6 | 6 | osimertinib 80 mg daily | 11.7 | true | MSS | 2026-03-15T05:35:59.288929+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_422478 | REC_0009833 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 14.9 | 72 | female | 1 | 24 | 8.8 | 2 | alectinib 600 mg BID | 25.2 | false | MSI-H | 2026-03-15T05:35:59.289167+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_255955 | REC_0009834 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 5.9 | 73 | female | 1 | 7 | 6.2 | 1 | sotorasib 960 mg daily | 18.8 | false | MSS | 2026-03-15T05:35:59.289397+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_575820 | REC_0009835 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 5.3 | 72 | female | 1 | 62 | 5.9 | 7 | carboplatin + paclitaxel + pembrolizumab | 11.3 | false | MSS | 2026-03-15T05:35:59.289628+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_893911 | REC_0009836 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 6.2 | 54 | male | 0 | 10 | 5.1 | 5 | osimertinib 80 mg daily | 4.3 | true | MSS | 2026-03-15T05:35:59.289871+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_327395 | REC_0009837 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 7.3 | 59 | male | 0 | 20 | 5.8 | 4 | alectinib 600 mg BID | 11.3 | false | MSS | 2026-03-15T05:35:59.290118+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_741744 | REC_0009838 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 5.1 | 86 | female | 3 | 46 | 6.9 | 6 | pembrolizumab 200 mg q3w | 10.8 | false | MSS | 2026-03-15T05:35:59.290362+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855409 | REC_0009839 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 11.4 | 73 | female | 1 | 15 | 6.8 | 4 | alectinib 600 mg BID | 8.6 | false | MSS | 2026-03-15T05:35:59.290613+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173089 | REC_0009840 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 14.3 | 65 | female | 1 | 9 | 6.2 | 5 | osimertinib 80 mg daily | 10.8 | false | MSI-H | 2026-03-15T05:35:59.290863+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_955965 | REC_0009841 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 15.4 | 60 | female | 1 | 15 | 4.9 | 2 | alectinib 600 mg BID | 8.8 | false | MSS | 2026-03-15T05:35:59.291103+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577912 | REC_0009842 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 8.9 | 70 | female | 2 | 10 | 5 | 5 | pembrolizumab 200 mg q3w | 10.9 | false | MSS | 2026-03-15T05:35:59.291436+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_682666 | REC_0009843 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 14.9 | 63 | male | 0 | 15 | 4.7 | 1 | alectinib 600 mg BID | 13.2 | true | MSI-H | 2026-03-15T05:35:59.291684+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_437251 | REC_0009844 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 3.5 | 72 | female | 2 | 25 | 6.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.3 | false | MSS | 2026-03-15T05:35:59.291929+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_267950 | REC_0009845 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 33 | 8.2 | 62 | female | 0 | 10 | 5.7 | 2 | osimertinib 80 mg daily | 28.7 | true | MSS | 2026-03-15T05:35:59.292232+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_951312 | REC_0009846 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 14.2 | 77 | female | 2 | 24 | 5.5 | 6 | pembrolizumab 200 mg q3w | 10.8 | true | MSI-H | 2026-03-15T05:35:59.292490+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_154002 | REC_0009847 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 15 | 14.2 | 84 | female | 1 | 24 | 6.4 | 7 | osimertinib 80 mg daily | 14.2 | false | MSS | 2026-03-15T05:35:59.292742+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_640800 | REC_0009848 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 13.7 | 68 | female | 1 | 6 | 5.3 | 6 | osimertinib 80 mg daily | 4.5 | true | MSI-H | 2026-03-15T05:35:59.292993+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_549431 | REC_0009849 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 16 | 6.7 | 62 | male | 1 | 32 | 6.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 5.5 | false | MSS | 2026-03-15T05:35:59.293245+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_464797 | REC_0009850 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 17 | 10.1 | 72 | female | 2 | 7 | 6.8 | 1 | osimertinib 80 mg daily | 13 | true | MSI-H | 2026-03-15T05:35:59.293509+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_831205 | REC_0009851 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 9.6 | 81 | female | 1 | 5 | 5 | 1 | osimertinib 80 mg daily | 25.1 | false | MSS | 2026-03-15T05:35:59.293758+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_202724 | REC_0009852 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 12.4 | 63 | male | 0 | 23 | 5.5 | 2 | osimertinib 80 mg daily | 11.1 | true | MSS | 2026-03-15T05:35:59.294013+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_468464 | REC_0009853 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 12.7 | 68 | female | 0 | 14 | 6 | 1 | sotorasib 960 mg daily | 19.6 | true | MSI-H | 2026-03-15T05:35:59.294273+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_817114 | REC_0009854 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 16 | 7.2 | 65 | male | 0 | 45 | 4 | 2 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:35:59.294528+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_761445 | REC_0009855 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 18.3 | 57 | male | 0 | 15 | 7 | 5 | sotorasib 960 mg daily | 5.7 | false | MSS | 2026-03-15T05:35:59.294912+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_248941 | REC_0009856 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 8.7 | 62 | female | 0 | 16 | 6.3 | 6 | entrectinib 600 mg daily | 9.2 | false | MSS | 2026-03-15T05:35:59.295183+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_265184 | REC_0009857 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 14 | 71 | male | 1 | 10 | 7.9 | 0 | entrectinib 600 mg daily | 20.6 | false | MSS | 2026-03-15T05:35:59.295441+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_670566 | REC_0009858 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 11.6 | 73 | female | 1 | 15 | 9.3 | 2 | osimertinib 80 mg daily | 19 | false | MSS | 2026-03-15T05:35:59.295692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_676202 | REC_0009859 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5 | 73 | female | 2 | 67 | 4.5 | 4 | carboplatin + paclitaxel + pembrolizumab | 8.8 | false | MSS | 2026-03-15T05:35:59.295937+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_270459 | REC_0009860 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 4.5 | 73 | female | 2 | 32 | 3.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 16.6 | true | MSS | 2026-03-15T05:35:59.296327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_319369 | REC_0009861 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 11.6 | 77 | female | 0 | 15 | 6.9 | 6 | sotorasib 960 mg daily | 16.5 | true | MSI-H | 2026-03-15T05:35:59.296603+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_162469 | REC_0009862 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 36 | 12.8 | 66 | female | 0 | 3 | 5.8 | 0 | sotorasib 960 mg daily | 17 | true | MSI-H | 2026-03-15T05:35:59.296873+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_879013 | REC_0009863 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 6.7 | 62 | female | 0 | 12 | 5.4 | 5 | pembrolizumab 200 mg q3w | 11.2 | false | MSS | 2026-03-15T05:35:59.297120+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_713613 | REC_0009864 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 5 | 75 | female | 2 | 14 | 6.2 | 6 | sotorasib 960 mg daily | 13.8 | true | MSS | 2026-03-15T05:35:59.297362+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_852992 | REC_0009865 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 14 | 82 | female | 1 | 13 | 6.8 | 6 | osimertinib 80 mg daily | 5.9 | false | MSS | 2026-03-15T05:35:59.297607+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_186095 | REC_0009866 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 19 | 10.6 | 71 | female | 1 | 28 | 6.4 | 0 | entrectinib 600 mg daily | 24.7 | false | MSI-H | 2026-03-15T05:35:59.297856+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_603470 | REC_0009867 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 11.8 | 71 | female | 1 | 0 | 5.2 | 7 | pembrolizumab 200 mg q3w | 12.2 | false | MSI-H | 2026-03-15T05:35:59.298103+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_603509 | REC_0009868 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.8 | 61 | male | 0 | 50 | 8.5 | 9 | carboplatin + paclitaxel + pembrolizumab | 5.2 | true | MSS | 2026-03-15T05:35:59.298452+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_255399 | REC_0009869 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 16 | 14.2 | 66 | female | 1 | 6 | 5.3 | 4 | alectinib 600 mg BID | 10.7 | false | MSI-H | 2026-03-15T05:35:59.298701+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_793302 | REC_0009870 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 17.2 | 72 | female | 1 | 5 | 4.2 | 1 | osimertinib 80 mg daily | 16 | false | MSI-H | 2026-03-15T05:35:59.298941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_783726 | REC_0009871 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 3.3 | 64 | female | 0 | 58 | 6 | 4 | pembrolizumab 200 mg q3w | 9.2 | true | MSS | 2026-03-15T05:35:59.299183+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843214 | REC_0009872 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 25 | 13.2 | 75 | female | 2 | 14 | 7.6 | 0 | alectinib 600 mg BID | 17.2 | true | MSS | 2026-03-15T05:35:59.299424+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_169735 | REC_0009873 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 8.7 | 60 | female | 1 | 13 | 2.5 | 1 | osimertinib 80 mg daily | 17.4 | false | MSS | 2026-03-15T05:35:59.299672+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_379021 | REC_0009874 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 9.6 | 76 | female | 3 | 21 | 5.1 | 3 | sotorasib 960 mg daily | 9.2 | false | MSS | 2026-03-15T05:35:59.299905+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_876102 | REC_0009875 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 17.7 | 65 | female | 1 | 13 | 5.7 | 6 | alectinib 600 mg BID | 4 | true | MSI-H | 2026-03-15T05:35:59.300195+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_656866 | REC_0009876 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 5.5 | 66 | female | 1 | 20 | 4.8 | 5 | entrectinib 600 mg daily | 8.6 | false | MSS | 2026-03-15T05:35:59.300448+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_866754 | REC_0009877 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 12.6 | 64 | female | 0 | 12 | 5.5 | 2 | alectinib 600 mg BID | 23.4 | false | MSS | 2026-03-15T05:35:59.300700+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_291007 | REC_0009878 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 31 | 5.9 | 59 | female | 0 | 37 | 4.9 | 3 | pembrolizumab 200 mg q3w | 15.4 | true | MSS | 2026-03-15T05:35:59.300952+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_405184 | REC_0009879 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 14 | 5.3 | 76 | female | 0 | 11 | 6.5 | 5 | pembrolizumab 200 mg q3w | 9.6 | false | MSS | 2026-03-15T05:35:59.301206+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_975879 | REC_0009880 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 7.5 | 74 | male | 2 | 12 | 6 | 5 | osimertinib 80 mg daily | 13.5 | false | MSS | 2026-03-15T05:35:59.301451+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_257330 | REC_0009881 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 20 | 7.9 | 63 | female | 0 | 47 | 4.4 | 7 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:35:59.301812+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_327015 | REC_0009882 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 31 | 11.5 | 60 | female | 0 | 21 | 5 | 2 | alectinib 600 mg BID | 4.3 | false | MSI-H | 2026-03-15T05:35:59.302078+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_753350 | REC_0009883 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 33 | 9 | 73 | male | 1 | 12 | 7.3 | 0 | pembrolizumab 200 mg q3w | 53.7 | true | MSS | 2026-03-15T05:35:59.302326+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_554318 | REC_0009884 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 3.5 | 62 | male | 1 | 18 | 4.6 | 5 | osimertinib 80 mg daily | 17.1 | false | MSS | 2026-03-15T05:35:59.302575+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_984923 | REC_0009885 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 19 | 7.1 | 81 | female | 2 | 41 | 3.8 | 7 | pembrolizumab 200 mg q3w | 8.3 | false | MSS | 2026-03-15T05:35:59.302817+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_330532 | REC_0009886 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 7.9 | 74 | female | 1 | 19 | 2.8 | 7 | sotorasib 960 mg daily | 13.8 | false | MSS | 2026-03-15T05:35:59.303057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_474643 | REC_0009887 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 5.8 | 71 | female | 1 | 31 | 5.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 12.5 | true | MSS | 2026-03-15T05:35:59.303305+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_440906 | REC_0009888 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 13.6 | 77 | female | 2 | 15 | 5.7 | 2 | osimertinib 80 mg daily | 15.6 | true | MSS | 2026-03-15T05:35:59.303548+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_779813 | REC_0009889 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 35 | 5.9 | 73 | female | 2 | 49 | 5.4 | 8 | carboplatin + paclitaxel + pembrolizumab | 5.1 | false | MSS | 2026-03-15T05:35:59.303791+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_435435 | REC_0009890 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 14.5 | 53 | male | 0 | 7 | 8.3 | 5 | osimertinib 80 mg daily | 8.7 | true | MSS | 2026-03-15T05:35:59.304039+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_688444 | REC_0009891 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 29 | 7.5 | 54 | female | 0 | 7 | 5.7 | 2 | pembrolizumab 200 mg q3w | 12.8 | false | MSS | 2026-03-15T05:35:59.304414+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_932181 | REC_0009892 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 4.7 | 83 | male | 1 | 34 | 4.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 13.2 | false | MSS | 2026-03-15T05:35:59.304701+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_943790 | REC_0009893 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 11.8 | 72 | male | 2 | 17 | 3.1 | 6 | sotorasib 960 mg daily | 18.2 | true | MSS | 2026-03-15T05:35:59.304958+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_778511 | REC_0009894 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 15.6 | 68 | female | 0 | 20 | 5.8 | 2 | osimertinib 80 mg daily | 26.4 | false | MSS | 2026-03-15T05:35:59.305327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_461227 | REC_0009895 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 3.6 | 75 | male | 2 | 14 | 6.8 | 3 | pembrolizumab 200 mg q3w | 6.9 | true | MSS | 2026-03-15T05:35:59.305583+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210174 | REC_0009896 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 7.4 | 59 | male | 0 | 17 | 4.2 | 8 | carboplatin + paclitaxel + pembrolizumab | 6.9 | true | MSS | 2026-03-15T05:35:59.305833+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_966419 | REC_0009897 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 3.7 | 59 | male | 0 | 53 | 4.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 23.6 | false | MSS | 2026-03-15T05:35:59.306078+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_530391 | REC_0009898 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 18.6 | 78 | female | 1 | 17 | 8.5 | 5 | sotorasib 960 mg daily | 6.5 | false | MSS | 2026-03-15T05:35:59.306323+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_564121 | REC_0009899 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 9.7 | 64 | female | 0 | 20 | 6.6 | 2 | alectinib 600 mg BID | 11.7 | true | MSS | 2026-03-15T05:35:59.306570+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_242468 | REC_0009900 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 18.4 | 70 | female | 1 | 8 | 3.8 | 7 | entrectinib 600 mg daily | 10.6 | false | MSS | 2026-03-15T05:35:59.306814+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.